Skip to main content
Svas Biosana logo

Svas Biosana — Investor Relations & Filings

Ticker · SVS ISIN · IT0005469264 LEI · 81560055A88E1D16D537 XMIL Manufacturing
Open in API
Filings indexed 284 across all filing types
Latest filing 2025-04-04 Transaction in Own Shar…
Country IT Italy
Listing XMIL SVS

About Svas Biosana

https://svas.it/en/

Svas Biosana is a company that specializes in the planning, manufacturing, and distribution of medical devices and pharmaceutical products. The company's portfolio includes a range of disposable hospital supplies, such as incontinence aids and traditional dressings. Serving both public and private health institutions, Svas Biosana develops, produces, and distributes its own branded products as well as those from third-party manufacturers.

Recent filings

Filing Released Lang Actions
Acquisto azioni proprie
Transaction in Own Shares Classification · 100% confidence The document is titled "INFORMATIVA SETTIMANALE ACQUISTO AZIONI PROPRIE" (Weekly Information on Own Share Purchase) and explicitly details the number of shares purchased by Svas Biosana S.p.A. during the period from March 31, 2025, to April 4, 2025, including daily transaction details and the resulting total holding of treasury shares. This activity—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. Therefore, the appropriate filing code is POS.
2025-04-04 Italian
Acquisto azioni proprie
Transaction in Own Shares Classification · 100% confidence The document is titled "INFORMATIVA SETTIMANALE ACQUISTO AZIONI PROPRIE" (Weekly Information on Own Share Purchase) and details transactions made by the company (Svas Biosana S.p.A.) to buy back its own shares during a specific period (March 24, 2025, to March 28, 2025). This activity directly corresponds to the definition of 'Transaction in Own Shares' (share repurchase). The filing code for this activity is POS. Although it is a weekly report, the specific nature of the content (share repurchase details) overrides a general regulatory filing code (RNS) or report publication announcement (RPA).
2025-03-28 Italian
Acquisto azioni proprie
Transaction in Own Shares Classification · 100% confidence The document is titled 'INFORMATIVA SETTIMANALE ACQUISTO AZIONI PROPRIE' (Weekly Information on Own Share Purchase) and details the number of shares purchased by Svas Biosana S.p.A. between March 10, 2025, and March 14, 2025, including daily transaction tables and the resulting total holding of treasury shares (5.0473%). This activity directly corresponds to the company buying back or selling its own shares, which matches the definition for 'Transaction in Own Shares' (POS). Although it is a weekly report, the core subject matter is the share repurchase program.
2025-03-14 Italian
Acquisto azioni proprie
Transaction in Own Shares Classification · 100% confidence The document is titled 'INFORMATIVA SETTIMANALE ACQUISTO AZIONI PROPRIE' (Weekly Information on Own Share Purchase) and details the number of shares purchased by Svas Biosana S.p.A. between March 10, 2025, and March 14, 2025, including daily transaction tables and the resulting total holding of treasury shares (5.0473%). This activity directly corresponds to the company buying back or selling its own shares, which matches the definition for 'Transaction in Own Shares' (POS). Although it is a weekly report, the core subject matter is the share repurchase program.
2025-03-14 Italian
Acquisto azioni proprie
Transaction in Own Shares Classification · 100% confidence The document is titled 'INFORMATIVA SETTIMANALE ACQUISTO AZIONI PROPRIE' (Weekly Information on Own Share Purchase) and details the number of shares purchased by Svas Biosana S.p.A. between March 10, 2025, and March 14, 2025, including daily transaction tables and the resulting total holding of treasury shares (5.0473%). This activity directly corresponds to the company buying back or selling its own shares, which matches the definition for 'Transaction in Own Shares' (POS). Although it is a weekly report, the core subject matter is the share repurchase program.
2025-03-14 Italian
CS_Svas Biosana comunica il Closing delle Acquisizioni di Hermes Pharma e Megapharm
Regulatory Filings Classification · 95% confidence The document is titled 'COMUNICATO STAMPA' (Press Release) and its main subject ('Oggetto') is 'CS_Svas Biosana comunica il Closing delle Acquisizioni di Hermes Pharma e Megapharm'. The text details the completion (closing) of two acquisitions, including financial considerations and preliminary financial data of the acquired entities. This type of announcement, which communicates a significant corporate event (M&A closing) via a press release, is generally classified as a general regulatory announcement or a specific corporate action announcement. Since the core event is the completion of an acquisition, it relates to M&A Activity (TAR). However, the document itself is a formal press release disseminated through regulatory channels ('Informazione Regolamentata n. 20240-9-2025', distributed via eMarket SDIR). Given the options, M&A Activity (TAR) is the most specific fit for the *content* (acquisition closing). If the content were purely about the announcement mechanism, RPA or RNS might apply, but the substance is clearly M&A. Since TAR covers merger proposals or takeover bids, and this is the closing of an acquisition, TAR is the most appropriate classification for the substance being reported.
2025-03-10 Italian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.